Postpartum Overdose Prevention Bundle
Purpose: Pregnancy-associated overdose mortality more than doubled between 2017 and 2020, reaching ~12 deaths per 100,000 live births. 60-73% of these deaths occur outside healthcare settings. This bundle provides an evidence-based protocol using the AIM 5-domain framework.
84% of pregnancy-related deaths are preventable. In Ohio, 91% of pregnancy-related overdose deaths were deemed preventable. The postpartum period—especially 7-12 months—represents the highest-risk window.
Evidence Map: Interventions Across Levels
Individual Level
- MOUD retention: 43.1% retention at 6 months with MOUD vs 28.9% without
- Naloxone distribution: 89% of postpartum people accepted take-home kits in Maine pilot
- Safety planning: Address tolerance status, fentanyl contamination risks, never-use-alone strategies
Clinic Level
- Rapid access and integrated care: 69% buprenorphine continuation at 6 months postpartum (VCU integrated model)
- Peer recovery specialists: Improve retention and care coordination
- Warm handoffs: Direct introduction between providers
System Level
- 12-month Medicaid postpartum extension: Increases Medicaid-financed MOUD months by 8.55%
- Tele-MOUD: Now permanently authorized via phone/video
Policy Level
- Punitive policies (criminalization): Associated with 43% higher odds of no planned MOUD
- Supportive policies: Treatment funding increased MOUD receipt by 11%
Six Points of Preventable Death
| Failure Point | Mechanism of Harm | Bundle Response |
|---|---|---|
| Missed MOUD initiation | No treatment started despite identified OUD | Universal SUD screening + same-day MOUD initiation |
| Early MOUD discontinuation | Insurance loss; stigma-driven discontinuation | 12-month Medicaid extension; MOUD continuity plan |
| Lack of naloxone | 60-73% deaths outside healthcare; no reversal agent | Universal naloxone dispense at discharge |
| Untreated depression/PTSD | Mental health conditions drive recurrence | Integrated behavioral health; screening at every visit |
| Intimate partner violence | IPV delays care and increases risk | HITS/HARK screening at every trimester + PP |
| Housing instability | Overdose decedents in deprived neighborhoods | SDOH screening; housing/food/transport connection |
Bundle Design: 5-Domain Protocol
TRIGGER: Every pregnant or postpartum person with known or suspected SUD/OUD
GOAL: Prevent overdose death through MOUD continuity, harm reduction, and wraparound support
1. READINESS (Every Unit)
- Naloxone kits stocked on L&D, postpartum, and triage units
- Staff trained in trauma-informed care and implicit bias (annual)
- MOUD formulary includes buprenorphine and methadone
- Peer recovery specialist and/or doula with lived experience on team
- Current referral directory: SUD tx, mental health, housing, IPV, WIC
- Standardized Plan of Safe Care template in EHR
2. RECOGNITION & SCREENING (Every Patient)
- Universal SUD screening with validated tool (4P's, NIDA Quick Screen) at first prenatal, each trimester, L&D admission, and postpartum
- Depression/anxiety screening (PHQ-9, GAD-7, EPDS) at same intervals
- IPV screening (HITS or HARK) at first prenatal, each trimester, and postpartum
- SDOH screening for housing, food, transportation, insurance
- Assess tolerance status: any recent abstinence, incarceration, detox? → HIGH risk
3. RESPONSE (Every Event)
A. MOUD Continuity Plan
- Initiate or continue MOUD; buprenorphine preferred for new starts
- Do NOT routinely taper postpartum
- At discharge: next MOUD appointment within 7 days; bridge Rx if needed
- Warm handoff to outpatient MOUD provider
B. Universal Naloxone Education + Dispense
- Educate patient + support person on overdose recognition and administration
- Dispense ≥2-dose nasal naloxone at discharge via standing order
- Include in take-home "first aid kit"
C. Harm Reduction Counseling
- Discuss fentanyl contamination in stimulants and pressed pills
- Never-use-alone counseling; safe use planning
- Review risk of reduced tolerance postpartum
D. Mental Health + IPV Pathway
- Positive screen → same-day warm handoff to behavioral health
- If IPV identified → safety planning + confidential referral to advocacy
E. Postpartum Follow-Up Schedule
| Visit | Timing | Core Elements |
|---|---|---|
| 1 | 7–14 days PP | MOUD check, mood, feeding, naloxone supply, safety planning |
| 2 | 6 weeks PP | Comprehensive; contraception, MOUD continuation, PHQ-9 |
| 3 | 3 months PP | MOUD retention assessment, mental health, SDOH update |
| 4+ | Ongoing | Coordinate with pediatric well-child visits |
4. REPORTING & SYSTEMS LEARNING (Every Unit)
- Track bundle compliance (% receiving each element)
- Monthly multidisciplinary huddle to review near-misses and OD events
- Participate in maternal mortality/morbidity review with SUD lens
- Disaggregate data by race, ethnicity, and payor to identify disparities
5. RESPECTFUL, EQUITABLE & SUPPORTIVE CARE (Every Encounter)
- Use person-first, non-stigmatizing language
- Include patient in all care decisions; respect right to refuse
- Do not condition MOUD access on participation in other services
- Acknowledge structural barriers (criminalization, racism, poverty)
Implementation Strategy
Phase 1: Readiness Assessment (Months 1-3)
- Gap analysis of current SUD screening, MOUD access, naloxone stocking
- Identify champions (OB, addiction medicine, nursing, social work, peer specialist)
- Train staff using AIM learning modules and implicit bias curriculum
- Build EHR order sets: MOUD inpatient orders, naloxone standing order, discharge template
Phase 2: Pilot (Months 4-9)
- Launch bundle on one L&D unit
- Weekly implementation team huddles
- Rapid-cycle PDSA testing
- Monthly data collection on process measures
Phase 3: Spread and Sustain (Months 10-18)
- Expand to additional units/sites
- Quarterly outcome measure reporting
- Annual reassessment based on emerging evidence
Measurement Plan
| Process Measures | Target | Outcome Measures | Target |
|---|---|---|---|
| % screened for SUD | ≥95% | MOUD continuation 6 weeks PP | ≥75% |
| % naloxone dispensed | ≥90% | MOUD continuation 6 months PP | ≥65% |
| % follow-up ≤14 days | ≥80% | OD events (quarterly) | Trending ↓ |
Teaching OSCE Cases
OSCE Case 1: "Missed MOUD Initiation on L&D"
Scenario: Tamara, 26yo G2P1 at 38 weeks, presents in active labor. Daily fentanyl use, no prenatal care, no SUD treatment. Asks "Am I going to get in trouble?"
Learner Tasks:
- Perform non-judgmental SUD assessment using validated screening tool
- Discuss MOUD options (buprenorphine induction postpartum vs methadone referral)
- Address fears about criminalization and CPS
- Initiate Plan of Safe Care collaboratively
- Provide naloxone education and ensure discharge with kit
OSCE Case 2: "Postpartum MOUD Discontinuation"
Scenario: Keisha, 31yo, 10 days PP after C-section. Stable on buprenorphine 16 mg throughout pregnancy. Medicaid expires at 60 days (no extension). PHQ-9 = 14. Partner "getting more aggressive."
Learner Tasks:
- Explore reasons for considering MOUD discontinuation using motivational interviewing
- Provide psychoeducation about protective effects of MOUD and elevated PP overdose risk
- Address depression screen with warm handoff to behavioral health
- Screen for and respond to IPV disclosure
- Develop insurance continuity plan (Medicaid extension application)